Key facts
- Biotech firms are targeting the US$610 billion longevity market.
- METiS TechBio CEO Lai Tsai-ta views aging as accumulated errors in human cells' genetic code.
- AI can be used to read, rewrite, and reverse cellular aging or slow the process.
- The process could begin by fixing immune cells like T cells.
Biotech companies are actively pursuing the US$610 billion longevity market, aiming to reverse the human aging process. Lai Tsai-ta, CEO of Beijing-based METiS TechBio, likens aging to software bugs accumulating in the genetic code of human cells. He believes these errors can be corrected through AI, which can be used to read, rewrite, and reverse cellular processes, or at least decelerate aging. The initial focus for this reprogramming could be on immune cells, such as T cells.